Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
Saved in:
| Main Authors: | Rossana Di Staso, Beatrice Casadei, Frederick L. Locke, Michael Jain, Timothy J. Voorhees, Adam S. Kittai, Mariana Bastos-Oreiro, Antonio Gutiérrez, Alejandro Martin Garcia-Sancho, Maria Jose Terol, Monica Mead, Michael J. Maranzano, Gloria Iacoboni, Pere Barba, Mi Kwon, Rebeca Bailen, Juan Luis Reguera-Ortega, Agrima Mian, Brian Hill, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Catherine Thieblemont, Steven Le Gouill, Riccardo Masetti, Davide Gori, Alessandro Broccoli, Pier Luigi Zinzani, Lisa Argnani |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-11-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-024-01183-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope
by: Lisa Argnani, et al.
Published: (2025-03-01) -
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment
by: Gloria Iacoboni, et al.
Published: (2024-10-01) -
CAR T-Cell Therapy: Paving the Path to a Brighter Future in LBCL
by: Frederick Locke
Published: (2023-03-01) -
Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example
by: Gloria Iacoboni, et al.
Published: (2024-12-01) -
Tailoring CAR surface density and dynamics to improve CAR-T cell therapy
by: Michael Hudecek, et al.
Published: (2025-04-01)